Notice of Award of a Single-Source Cooperative Agreement To Fund Institut Pasteur de Cote d'Ivoire (IPCI)
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Issuing agencies
Abstract
The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces the award of approximately $1,000,000, for Year 1 of funding to the IPCI to sustain decentralization of HIV-associated microbiology at regional hospitals and to expand interventions to additional regional hospitals. The award will improve support to and the coordination of the TB and OIs laboratory network for quality assured diagnosis of TB/DR-TB, including smear microscopy (LED), Lipoarabinomannan Assay (LF-LAM) for the diagnosis and screening of active tuberculosis in people with HIV, solid and liquid culture, and molecular WHO-recommended diagnostic tests (LIPA, Xpert Ultra). Funding amounts for years 2-5 will be set at continuation.
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 45 (Tuesday, March 8, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 45 (Tuesday, March 8, 2022)]
[Notices]
[Pages 12964-12965]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-04790]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Notice of Award of a Single-Source Cooperative Agreement To Fund
Institut Pasteur de Cote d'Ivoire (IPCI)
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC), located
within the Department of Health and Human Services (HHS), announces the
award of approximately $1,000,000, for Year 1 of funding to the IPCI to
sustain decentralization of HIV-associated microbiology at regional
hospitals and to expand interventions to additional
[[Page 12965]]
regional hospitals. The award will improve support to and the
coordination of the TB and OIs laboratory network for quality assured
diagnosis of TB/DR-TB, including smear microscopy (LED),
Lipoarabinomannan Assay (LF-LAM) for the diagnosis and screening of
active tuberculosis in people with HIV, solid and liquid culture, and
molecular WHO-recommended diagnostic tests (LIPA, Xpert Ultra). Funding
amounts for years 2-5 will be set at continuation.
DATES: The period for this award will be September 30, 2022 through
September 29, 2027.
FOR FURTHER INFORMATION CONTACT: Titania Techeira, Center for Global
Health, Centers for Disease Control and Prevention, CDC C[ocirc]te
d'Ivoire, U.S. Embassy B.P. 730 Abidjan Cidex 03, Telephone: 800-232-
6348, Email: <a href="/cdn-cgi/l/email-protection#5c3529246e1c3f383f723b332a"><span class="__cf_email__" data-cfemail="58312d206a183b3c3b763f372e">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: The single-source award will strengthen IPCI
as the National Reference Laboratory for TB and microbiology tests.
This will enable IPCI to better and further sustain the efforts in 27
Anti-Tuberculosis Centers (CATs) and in 16 regional reference
laboratories previously supported for decentralized microbiology
diagnosis.
IPCI is in a unique position to conduct this work as it is the
designated laboratory institution in charge of integrated Disease
Surveillance and Response (IDSR) in Cote d'Ivoire by the Ministry of
Health (MOH) and Ministry of Scientific Research. IPCI is responsible
for the implementation, monitoring, and evaluation of population-based
TB, malaria and epidemic disease surveillance, including HIV
opportunistic infections, as well as prevention and care policies and
interventions.
Summary of the Award
Recipient: IPCI.
Purpose of the Award: The purpose of this award is to sustain
decentralization of HIV-associated microbiology at regional hospitals
and to expand interventions to additional regional hospitals. It will
improve support to and the coordination of the TB and OIs laboratory
network for quality assured diagnosis of TB/DR-TB, including smear
microscopy (LED), Lipoarabinomannan Assay (LF-LAM) for the diagnosis
and screening of active tuberculosis in people with HIV, solid and
liquid culture, and molecular WHO-recommended diagnostic tests (LIPA,
Xpert Ultra).
Amount of Award: The approximate year 1 funding amount will be
$1,000,000 in Federal Fiscal Year (FYY) 2022 funds, subject to the
availability of funds. Funding amounts for years 2-5 will be set at
continuation.
Authority: Public Law 108-25 (the United States Leadership Against
HIV AIDS, Tuberculosis and Malaria Act of 2003).
Period of Performance: September 30, 2022 through September 29,
2027.
Dated: March 2, 2022.
Terrance Perry,
Chief Grants Management Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2022-04790 Filed 3-7-22; 8:45 am]
BILLING CODE 4163-18-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.